Literature DB >> 8858069

The economic impact of ALS.

L M Klein1, D A Forshew.   

Abstract

ALS is a progressive degenerative neuromuscular disease for which there is no known cause, treatment, or cure. The steady disease progression of muscle weakness eventually causes paralysis, disabling the patient. Day-to-day patient care and management most frequently fall to family members. The resultant financial burden can be enormous. We review financial issues related to the diagnosis, management of disease progression, and issues of life support. Cost-effective solutions are discussed. It is believed the key to reduction of costs is education of the health care community, patients and families, and third-party payers.

Entities:  

Mesh:

Year:  1996        PMID: 8858069     DOI: 10.1212/wnl.47.4_suppl_2.126s

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  7 in total

1.  Spinal muscular atrophy--type I.

Authors:  M K M Hardart; R D Truog
Journal:  Arch Dis Child       Date:  2003-10       Impact factor: 3.791

Review 2.  Economic Studies in Motor Neurone Disease: A Systematic Methodological Review.

Authors:  Alan Moore; Carolyn A Young; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

Review 3.  Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease.

Authors:  Louisa Ng; Fary Khan; Carolyn A Young; Mary Galea
Journal:  Cochrane Database Syst Rev       Date:  2017-01-10

4.  Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy.

Authors:  Karsten Schepelmann; Yaroslav Winter; Annika E Spottke; Detlef Claus; Christoph Grothe; Rolf Schröder; Dieter Heuss; Stefan Vielhaber; Veit Mylius; Reinhard Kiefer; Bertold Schrank; Wolfgang H Oertel; Richard Dodel
Journal:  J Neurol       Date:  2009-07-24       Impact factor: 4.849

Review 5.  Cost effectiveness of treatments for amyotrophic lateral sclerosis: a review of the literature.

Authors:  Gary Ginsberg; Serena Lowe
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  Identification of personal factors in motor neurone disease: a pilot study.

Authors:  Louisa Ng; Fary Khan
Journal:  Rehabil Res Pract       Date:  2011-07-07

7.  Medical cost and healthcare utilization of amyotrophic lateral sclerosis in China: A cohort study based on hospital data from 2015 to 2018.

Authors:  Han Song; Jian-Chao Liu; Zi-Peng Cao; Wen-Jing Luo; Jing-Yuan Chen
Journal:  Medicine (Baltimore)       Date:  2020-11-20       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.